000282472 001__ 282472
000282472 005__ 20251121165706.0
000282472 0247_ $$2doi$$a10.1007/s00330-025-12001-5
000282472 0247_ $$2pmid$$apmid:40968298
000282472 0247_ $$2ISSN$$a0938-7994
000282472 0247_ $$2ISSN$$a1432-1084
000282472 0247_ $$2ISSN$$a1613-3749
000282472 0247_ $$2ISSN$$a1613-3757
000282472 0247_ $$2ISSN$$a(ISSN
000282472 0247_ $$2ISSN$$aDES
000282472 0247_ $$2ISSN$$aSUPPLEMENTS)
000282472 037__ $$aDZNE-2025-01295
000282472 041__ $$aEnglish
000282472 082__ $$a610
000282472 1001_ $$aWawer Matos Reimer, Robert P$$b0
000282472 245__ $$aSafety and evidence of CO2 as a vascular contrast agent as an alternative to iodine-based contrast media in vascular procedures: a systematic review by the ESUR Contrast Medium Safety Committee.
000282472 260__ $$aHeidelberg$$bSpringer$$c2025
000282472 3367_ $$2DRIVER$$aarticle
000282472 3367_ $$2DataCite$$aOutput Types/Journal article
000282472 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763740579_6324
000282472 3367_ $$2BibTeX$$aARTICLE
000282472 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282472 3367_ $$00$$2EndNote$$aJournal Article
000282472 520__ $$aThis systematic review aims to analyse the different safety aspects and evidence of CO2 as a contrast agent in vascular applications as an alternative to iodine-based contrast media (ICM). The review addresses clinical applications, contraindications, safety measures, and the impact of CO2 on the risk reduction of contrast-associated acute kidney injury (CA-AKI).A systematic literature search was conducted across PubMed, Web of Science, Embase, and Cochrane Library, focusing on relevant literature centred around clinical questions by the Contrast Media Safety Committee of the European Society of Urogenital Radiology.Eleven studies encompassing meta-analyses, randomised controlled trials, and comparative studies were included. The review found that CO2 angiography is a safe alternative to ICM in various vascular applications, especially in patients at risk for CA-AKI. CO2 is associated with a higher incidence of minor, non-serious adverse events compared to ICM. No critical dose for CO2 is established, but safe administration protocols and measures were outlined. CO2 demonstrated a lower incidence of CA-AKI in peripheral arterial disease (PAD) procedures, but evidence in endovascular aneurysm repair (EVAR) was less conclusive.CO2 is a safe alternative to ICM in vascular procedures, potentially reducing the risk of CA-AKI, especially in PAD procedures. However, more large-scale RCTs are needed to confirm these findings and further investigate other risk factors contributing to CA-AKI in both EVAR and PAD procedures.Question What safety aspects and evidence support CO2 use as a contrast agent in vascular applications instead of ICM? Findings CO2 angiography is safe when considering specific safety measures and clinical applications; evidence on the reduction of ICM volume and CA-AKI is limited. Clinical relevance CO2 angiography offers an alternative to ICM, especially in CA-AKI risk patients. More large-scale, multicentre RCTs are required to strengthen the evidence and to investigate other risk factors due to a high residual risk of CA-AKI when using CO2 angiography.
000282472 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282472 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282472 650_7 $$2Other$$aAcute kidney injury
000282472 650_7 $$2Other$$aAngiography
000282472 650_7 $$2Other$$aCarbon dioxide
000282472 650_7 $$2Other$$aContrast media
000282472 650_7 $$2Other$$aSafety
000282472 650_7 $$2NLM Chemicals$$aContrast Media
000282472 650_7 $$0142M471B3J$$2NLM Chemicals$$aCarbon Dioxide
000282472 650_7 $$09679TC07X4$$2NLM Chemicals$$aIodine
000282472 650_2 $$2MeSH$$aContrast Media: adverse effects
000282472 650_2 $$2MeSH$$aHumans
000282472 650_2 $$2MeSH$$aCarbon Dioxide: adverse effects
000282472 650_2 $$2MeSH$$aCarbon Dioxide: administration & dosage
000282472 650_2 $$2MeSH$$aIodine: adverse effects
000282472 650_2 $$2MeSH$$aAcute Kidney Injury: chemically induced
000282472 650_2 $$2MeSH$$aAcute Kidney Injury: prevention & control
000282472 650_2 $$2MeSH$$aAngiography: methods
000282472 650_2 $$2MeSH$$aAngiography: adverse effects
000282472 7001_ $$aReimer, Peter$$b1
000282472 7001_ $$00000-0001-8077-9306$$aMahnken, Andreas H$$b2
000282472 7001_ $$aBellin, Marie-France$$b3
000282472 7001_ $$aBertolotto, Michele$$b4
000282472 7001_ $$aBrismar, Torkel$$b5
000282472 7001_ $$aCorreas, Jean-Michel$$b6
000282472 7001_ $$0P:(DE-2719)9001745$$aDeike-Hofmann, Katerina$$b7
000282472 7001_ $$aDekkers, Ilona A$$b8
000282472 7001_ $$aGeenen, Remy W F$$b9
000282472 7001_ $$aHeinz-Peer, Gertraud$$b10
000282472 7001_ $$aMallio, Carlo A$$b11
000282472 7001_ $$avan der Molen, Aart J$$b12
000282472 7001_ $$aQuattrocchi, Carlo C$$b13
000282472 7001_ $$0P:(DE-2719)9001861$$aRadbruch, Alexander$$b14$$udzne
000282472 7001_ $$aRoditi, Giles$$b15
000282472 7001_ $$aRomanini, Laura$$b16
000282472 7001_ $$aSebastià, Carmen$$b17
000282472 7001_ $$aStacul, Fulvio$$b18
000282472 7001_ $$aClement, Olivier$$b19
000282472 773__ $$0PERI:(DE-600)1472718-3$$a10.1007/s00330-025-12001-5$$gVol. 35, no. 12, p. 7680 - 7687$$n12$$p7680 - 7687$$tEuropean radiology$$v35$$x0938-7994$$y2025
000282472 8564_ $$uhttps://pub.dzne.de/record/282472/files/DZNE-2025-01295.pdf$$yRestricted
000282472 8564_ $$uhttps://pub.dzne.de/record/282472/files/DZNE-2025-01295.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282472 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001745$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000282472 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001861$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000282472 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282472 9141_ $$y2025
000282472 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-28$$wger
000282472 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-28$$wger
000282472 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR RADIOL : 2022$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-28
000282472 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR RADIOL : 2022$$d2024-12-28
000282472 9201_ $$0I:(DE-2719)5000075$$kAG Radbruch$$lClinical Neuroimaging$$x0
000282472 980__ $$ajournal
000282472 980__ $$aEDITORS
000282472 980__ $$aVDBINPRINT
000282472 980__ $$aI:(DE-2719)5000075
000282472 980__ $$aUNRESTRICTED